Threats: Intense competition and patent expirations leading to generic competition.

"Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company that develops diabetes, oncology, immunology and ...

Here's why Eli Lilly is a no-brainer stock to buy on the dip ... Sales for breast cancer drug Verzenio jumped 32% year over ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Here's why Eli Lilly is a no-brainer stock to buy on the ... Sales for breast cancer drug Verzenio jumped 32% year over year to $1.37 billion in Q3. Meanwhile, autoimmune disease drug Taltz ...

The stock of Eli Lilly and Company LLY has declined 10.6% in a month ... Lilly’s revenue growth is being driven by higher ...

Eli Lilly stock (NYSE: LLY ... fell short of our estimates of $3.5 billion and $1.5 billion, respectively. Verzenio took in $1.4 billion in sales, slightly better than our estimate of $1.3 ...